IP Portfolio
Protecting what we design
Axia Discovery has filed nine U.S. provisional patent applications in 2026, establishing a patent-pending pipeline of de novo-designed cyclic peptide therapeutics across five therapeutic areas and eight programs, with PCT international filings anticipated.
Nine applications filed in 2026
U.S. provisional patent applications covering novel de novo-designed cyclic peptide compositions across CNS, oncology (radioligand therapy), cardiometabolic, and renal indications. Further filings staged as programs advance.
PCT international filings anticipated
Provisional applications establish priority dates. PCT international filings are planned to extend protection across key jurisdictions in line with partnering strategy.
Composition of matter
Filings protect the novel cyclic peptide compositions we design — covering the molecules themselves across their targeted indications.
Disclosed responsibly
Specific sequences, structural details, and claim language remain confidential until applications publish — standard practice for early-stage, file-first IP. Detailed status is shared under CDA.
Patent-pending programs
| Program | Modality | Status |
|---|---|---|
| AX-GRM1 | Cyclic peptide antagonist | Patent pending |
| AX-HTR2C-ANT | Cyclic peptide antagonist | Patent pending |
| AX-HTR2C-AGO | Cyclic peptide agonist | Patent pending |
| AX-GPRC5D | Cyclic peptide · RLT | Patent pending |
| AX-GPR160 | Cyclic peptide · RLT | Patent pending |
| AX-KISS1R | Cyclic peptide · RLT | Patent pending |
| AX-APLNR | Cyclic peptide agonist | Patent pending |
| AX-CASR | Cyclic peptide · calcimimetic (PAM) | Patent pending |
Nine U.S. provisional patent applications filed 2026 (eight programs disclosed) · Application numbers confidential · PCT international filings anticipated
Full IP status — targets, sequences, and claim scope — shared under CDA.
Published and granted patents will be listed here as they issue.
Request CDA / Diligence Package